CM Management’s Amicus Therapeutics FOLD Stock Holding History

CM Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-370,000	Closed	-$5.27M	–	75
2025 Q4	$5.27M	Sell	370,000 -80,000	-18%	-$786K	4.44%	4
2025 Q3	$3.55M	Hold	450,000	–	–	2.96%	6
2025 Q2	$2.58M	Hold	450,000	–	–	2.35%	10
2025 Q1	$3.67M	Hold	450,000	–	–	3.69%	6
2024 Q4	$4.24M	Hold	450,000	–	–	3.79%	5
2024 Q3	$4.81M	Hold	450,000	–	–	3.84%	4
2024 Q2	$4.46M	Hold	450,000	–	–	4.1%	3
2024 Q1	$5.3M	Hold	450,000	–	–	4.45%	3
2023 Q4	$6.39M	Hold	450,000	–	–	5.13%	2
2023 Q3	$5.47M	Hold	450,000	–	–	5.81%	2
2023 Q2	$5.65M	Hold	450,000	–	–	5.51%	2
2023 Q1	$4.99M	Hold	450,000	–	–	5.93%	2
2022 Q4	$5.5M	Hold	450,000	–	–	6.56%	1
2022 Q3	$4.7M	Hold	450,000	–	–	5.24%	2
2022 Q2	$4.83M	Hold	450,000	–	–	5.14%	2
2022 Q1	$4.26M	Hold	450,000	–	–	3.58%	6
2021 Q4	$5.2M	Hold	450,000	–	–	3.93%	5
2021 Q3	$4.3M	Hold	450,000	–	–	3.21%	6
2021 Q2	$4.34M	Hold	450,000	–	–	3.14%	7
2021 Q1	$4.45M	Buy	450,000 +360,000	+400%	+$5.57M	3.3%	6
2020 Q4	$2.08M	Buy	+90,000	New	+$1.84M	1.93%	16

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

CM Management's FOLD Position: Q1 2026 in Review

CM Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 370,000 shares — an estimated $5.27M sold.

CM Management first reported a position in FOLD in Q4 2020 and held it in 21 quarters. The position peaked at $6.39M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

CM Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
CM Management sold 370,000 Amicus Therapeutics shares in Q1 2026, an estimated $5.27M.
CM Management first reported a position in Amicus Therapeutics in Q4 2020 and held it in 21 quarters.
CM Management's Amicus Therapeutics position peaked at $6.39M in Q4 2023.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on CM Management's 13F filing for Q1 2026, filed 8 May 2026.